Tag Archives: Jayson Bedford

Edwards Lifesciences (EW) Received its Third Buy in a Row

After Wells Fargo and Cowen & Co. gave Edwards Lifesciences (NYSE: EW) a Buy rating last month, the company received another Buy, this time from Raymond James. Analyst Jayson Bedford maintained a Buy rating on Edwards Lifesciences today and set

Medtronic (MDT) Receives a Rating Update from a Top Analyst

In a report released today, Jayson Bedford from Raymond James maintained a Buy rating on Medtronic (MDT – Research Report), with a price target of $104. The company’s shares closed yesterday at $92.16. According to TipRanks.com, Bedford is a top

Raymond James Believes Boston Scientific Corp (NYSE: BSX) Still Has Room to Grow

In a report released today, Jayson Bedford from Raymond James maintained a Buy rating on Boston Scientific Corp (NYSE: BSX), with a price target of $34. The company’s shares opened today at $29.57, close to its 52-week high of $29.93.

Raymond James Assigns a Buy Rating on Viveve Medical Inc

Raymond James analyst Jayson Bedford assigned a Buy rating to Viveve Medical Inc (NASDAQ: VIVE) yesterday. The company’s shares closed yesterday at $4.94, close to its 52-week low of $3.75. Bedford said: “We recently hosted senior management and came away

Cardiovascular Systems Receives a Hold from Raymond James

Raymond James analyst Jayson Bedford assigned a Hold rating to Cardiovascular Systems (NASDAQ: CSII) today. The company’s shares closed on Friday at $24.75. Bedford commented: “We traveled late last week with CEO Scott Ward and Jack Neilson. While there were

Raymond James Releases a Hold Rating on Dexcom

In a report issued on November 29, Jayson Bedford from Raymond James assigned a Hold rating to Dexcom (NASDAQ: DXCM). The company’s shares closed on Friday at $58.02. According to TipRanks.com, Bedford is a 5-star analyst with an average return